Loss of programmed cell death 4 expression marks adenoma‐carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer
Open Access
- 19 September 2007
- Vol. 110 (8) , 1697-1707
- https://doi.org/10.1002/cncr.22983
Abstract
BACKGROUND. Programmed cell death 4 (Pdcd4) inhibits malignant transformation, and initial studies of Pdcd4 suggested the regulation of Pdcd4 localization by protein kinase B (Akt). However, supporting patient tissue data are missing, and the diagnostic/prognostic potential of Pdcd4 rarely has been studied. The objectives of the current were 1) to determine Pdcd4 as a diagnostic marker in the adenoma-carcinoma sequence, 2) to support phosphorylated Akt (pAkt)-mediated Pdcd4 regulation in vivo, and 3) to obtain the first prognostic evidence of Pdcd4 in colorectal cancer. METHODS. Tumor samples and normal tissues from 71 patients with colorectal cancer who were followed prospectively (median follow-up, 36 months) and 42 adenomas were analyzed for Pdcd4, Akt, and pAkt in immunohistochemical and Western blot analyses. RESULTS. A significant reduction in Pdcd4 was observed between normal mucosa and adenomas and between adenomas and tumor samples (P < .01 and P < .01, respectively). Normal mucosa demonstrated strong nuclear Pdcd4, which was reduced significantly in adenomas (P < .01) and almost was lost in tumors (P < .01). pAkt was correlated inversely with Pdcd4 and with the transition of Pdcd4 from nucleus to cytoplasm (P < .01). Kaplan-Meier analysis (using the Mantel-Cox log-rank test) indicated a significant correlation between the loss of total and nuclear Pdcd4 in tumors and overall survival (P < .05 and P < .02, respectively) and disease-specific survival (P < .01 and P < .01, respectively). In multivariate analysis, loss of total or nuclear Pdcd4 was an independent predictor of disease-specific or overall survival. CONCLUSIONS. To the authors' knowledge, this is the first study to demonstrate an independent prognostic impact of Pdcd4 and its expression pattern in colorectal cancer. Data from this study support the regulation of Pdcd4 localization by pAkt in vivo. Pdcd4 immunohistochemistry may be useful as a supportive diagnostic tool for the transition between normal, adenoma, and tumor tissues. Cancer 2007. Published 2007 by the American Cancer Society.Keywords
This publication has 28 references indexed in Scilit:
- S6K1- and ßTRCP-Mediated Degradation of PDCD4 Promotes Protein Translation and Cell GrowthScience, 2006
- Urokinase-Receptor (u-PAR)–An Essential Player in Multiple Games of Cancer: A Review on Its Role in Tumor Progression, Invasion, Metastasis, Proliferation/dormancy, Clinical Outcome and Minimal Residual DiseaseCell Cycle, 2006
- Akt Phosphorylates and Regulates Pdcd4 Tumor Suppressor ProteinCancer Research, 2005
- Mutational analysis of the DEAD-box RNA helicase eIF4AII characterizes its interaction with transformation suppressor Pdcd4 and eIF4GIRNA, 2005
- The Transformation Suppressor Pdcd4 Is a Novel Eukaryotic Translation Initiation Factor 4A Binding Protein That Inhibits TranslationMolecular and Cellular Biology, 2003
- Up-regulation of PDCD4 in senescent human diploid fibroblastsBiochemical and Biophysical Research Communications, 2002
- Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitorOncogene, 2001
- A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-κB or ODC transactivationOncogene, 2001
- Molecular Cloning of the Genes Suppressed in RVC Lymphoma Cells by Topoisomerase InhibitorsBiochemical and Biophysical Research Communications, 1996
- Isolation of a novel mouse gene MA-3 that is induced upon programmed cell deathGene, 1995